The inhalable dry powder measles vaccine eliminates the need for painful injection and other concerns that characterize vaccination administered via injection. The experimental vaccine did not also cause significant side effects in its Phase 1 clinical trial. (Courtesy Photo)
Dr. Donald Brown holds the human papillomavirus vaccine Gardasil in his hand at his Chicago office Monday, Aug. 28, 2006 .(AP/Charles Rex Arbogast)


(The Monitor Daily) — A study published in the Science journal on Friday by a mixed team showcased the results of an experimental vaccine which seems to be on track of providing a safeguard against the spread of HIV, representing one of the biggest steps forward in this regard in history.

The HIV vaccine, developed by a combined team from The Rockefeller University, The Scrips Research Institute(TSRI) and the International AIDS Vaccine Initiative (IAVI) has had satisfactory results after being tested on mice, with its goal being to stimulate the production antibodies needed to stop or prevent HIV infection. The research was led by a trio consisting of TSRI Department of Immunology chair Dennis Burton, IAVI Director of Vaccine Design William Schief and Professor David Nemazee of TSRI.



Leave a comment

Your email address will not be published. Required fields are marked *

Yes, I would like to receive emails from Washington Informer Newspaper. Sign me up!

By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact